These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 15472793

  • 1. Progression of lipodystrophy (LD) with continued thymidine analogue usage: long-term follow-up from a randomized clinical trial (the PIILR study).
    Martin A, Smith D, Carr A, Hoy J, Chuah J, Mallal S, Law M, Clements M, Cooper DA, PIILR Study Group.
    HIV Clin Trials; 2004; 5(4):192-200. PubMed ID: 15472793
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy.
    Saint-Marc T, Partisani M, Poizot-Martin I, Bruno F, Rouviere O, Lang JM, Gastaut JA, Touraine JL.
    AIDS; 1999 Sep 10; 13(13):1659-67. PubMed ID: 10509567
    [Abstract] [Full Text] [Related]

  • 7. Relationships between drug exposure, changes in metabolic parameters and body fat in HIV-infected patients switched to a nucleoside sparing regimen.
    Autar RS, Boyd MA, Wit FW, Ruxrungthams K, Sankote J, Lange J, Cooper DA, Phanuphak P, Burger DM, Reiss P.
    Antivir Ther; 2007 Sep 10; 12(8):1265-71. PubMed ID: 18240866
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Normalization of fat accrual in lipoatrophic, HIV-infected children switched from stavudine to tenofovir and from protease inhibitor to efavirenz.
    Viganò A, Brambilla P, Cafarelli L, Giacomet V, Borgonovo S, Zamproni I, Zuccotti G, Mora S.
    Antivir Ther; 2007 Sep 10; 12(3):297-302. PubMed ID: 17591019
    [Abstract] [Full Text] [Related]

  • 12. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial.
    Carr A, Workman C, Smith DE, Hoy J, Hudson J, Doong N, Martin A, Amin J, Freund J, Law M, Cooper DA, Mitochondrial Toxicity (MITOX) Study Group.
    JAMA; 2002 Jul 10; 288(2):207-15. PubMed ID: 12095385
    [Abstract] [Full Text] [Related]

  • 13. Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study.
    Podzamczer D, Ferrer E, Sanchez P, Gatell JM, Crespo M, Fisac C, Lonca M, Sanz J, Niubo J, Veloso S, Llibre JM, Barrufet P, Ribas MA, Merino E, Ribera E, Martínez-Lacasa J, Alonso C, Aranda M, Pulido F, Berenguer J, Delegido A, Pedreira JD, Lérida A, Rubio R, del Río L, ABCDE (Abacavir vs. d4T (stavudine) plus efavirenz) Study Team.
    J Acquir Immune Defic Syndr; 2007 Feb 01; 44(2):139-47. PubMed ID: 17106274
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.